Engineering ECM-Responsive Nanomedicine to Overcome Tumor Stromal Barriers

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapy

Background:

• Tumor stromal barriers, including the extracellular matrix (ECM), impede nanomedicine penetration and drug distribution in solid tumors.
• Dense stromal architecture, characterized by excessive collagen and hyaluronic acid, limits therapeutic access within the tumor microenvironment.
• Current nanocarrier systems often fail to achieve effective intratumoral drug delivery beyond perivascular regions due to these barriers.

Purpose of the Study:

• To review recent advances in engineering extracellular matrix (ECM)-responsive nanomedicine to overcome tumor stromal barriers.
• To highlight strategies for transforming the ECM into a programmable interface for enhanced nanomedicine delivery.
• To discuss complementary approaches like enzyme-mediated stromal remodeling and cancer-associated fibroblast reprogramming.

Main Methods:

• Development of nanomedicine platforms with ECM-targeting ligands and protease-responsive activation.
• Integration of physically adaptive carrier architectures for improved penetration.
• Enzyme-mediated strategies for stromal remodeling and cancer-associated fibroblast reprogramming.
• Utilizing spatial omics and ECM-mimetic modeling for rational design.

Main Results:

• ECM-responsive nanomedicine enables selective activation, enhanced stromal penetration, and controlled drug release.
• Stromal remodeling strategies restore interstitial transport and improve intratumoral drug distribution.
• These engineered systems transform the ECM from a barrier into a therapeutic interface.

Conclusions:

• Engineering ECM-responsive nanomedicine is crucial for overcoming delivery challenges in solid tumors.
• Advances facilitate a shift from passive accumulation to programmable stromal interface engineering.
• This approach promises more effective cancer nanomedicine by improving drug delivery and therapeutic accessibility.